A collaboration with Merck or Eli Lilly will definitely propel KTOV’s value as a company while also vastly improving the chances of NT-219 being effective in Clinical trials with Cetuximab or Pembrolizumab (aka Keytruda). 

$KTOV $MRK $LLY